Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Santarus, Inc. today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS (budesonide) 6 mg tablets will be featured in four poster presentations at the Digestive Disease Week (DDW) Meeting being held at the San Diego Convention Center on May 19 - 22, 2012.

19 May 2012

Esperance initiates enrollment in EP-100 and paclitaxel Phase 2 combination trial for ovarian cancer

Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer.

18 May 2012

SQI closes second tranche of private placement

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today it has raised gross proceeds of CDN $2.333 million through the second tranche of a non-brokered private placement of 1,333,428 units priced at $1.75 per Unit.

18 May 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

Inovio SynCon avian influenza vaccine demonstrates broad coverage

Inovio Pharmaceuticals, Inc. announced today that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.

17 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Biologists engineer algae to produce potential candidates for malarial vaccine

Biologists at the University of California, San Diego have succeeded in engineering algae to produce potential candidates for a vaccine that would prevent transmission of the parasite that causes malaria, an achievement that could pave the way for the development of an inexpensive way to protect billions of people from one of the world's most prevalent and debilitating diseases. Initial proof-of-principle experiments suggest that such a vaccine could prevent malaria transmission.

17 May 2012

Dako, VARI partner to license, manufacture and distribute cancer diagnostics

Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 Antibody.

17 May 2012

Combination of daclizumab and vaccine improves survival of breast cancer patients

A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab.

17 May 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

New Liquid ready-to-use Tumour Marker Control available now from Randox

The new Randox Acusera multi-analyte Liquid Tumour Marker Control covers a total of 15 commonly tested and esoteric cancer antigens and tumour markers. The addition of assayed target values enables laboratories to effectively monitor both accuracy and precision.

From Randox Laboratories Ltd. 15 May 2012

New insights into how body's innate immunity is triggered to create effective immune response

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity".

11 May 2012

FDA advisory committee supports lorcaserin for weight management

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals.

11 May 2012

New discovery platform for antigen-specific monoclonal antibodies

Cell Signaling Technology, Inc. of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies.

From Cell Signaling Technology 11 May 2012

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

11 May 2012

African-Americans with scleroderma have more antibodies linked to severe complications

A new analysis finds that compared to Caucasians, African-Americans with systemic scleroderma have more antibodies in the blood that are linked to severe complications and an increased likelihood of death. They say this finding, published today in Arthritis & Rheumatism, suggests physicians can use these disease markers to screen and treat scleroderma patients proactively.

11 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

Rituximab does not appear to benefit children with INS

The drug rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis, has recently emerged as a potential treatment for a childhood kidney disorder known as idiopathic nephrotic syndrome.

11 May 2012

Eisai, Arena announce expansion of lorcaserin marketing and supply agreement

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug candidate intended for weight management.

11 May 2012

African Americans have more severe complications from scleroderma

African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), show that compared with Caucasians, African-American patients were more likely to have antibodies that increased frequency and severity of pulmonary fibrosis, which is associated with decreased survival.

10 May 2012